277 related articles for article (PubMed ID: 24661308)
1. Quantification of transthyretin kinetic stability in human plasma using subunit exchange.
Rappley I; Monteiro C; Novais M; Baranczak A; Solis G; Wiseman RL; Helmke S; Maurer MS; Coelho T; Powers ET; Kelly JW
Biochemistry; 2014 Apr; 53(12):1993-2006. PubMed ID: 24661308
[TBL] [Abstract][Full Text] [Related]
2. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
Wiseman RL; Green NS; Kelly JW
Biochemistry; 2005 Jun; 44(25):9265-74. PubMed ID: 15966751
[TBL] [Abstract][Full Text] [Related]
3. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
4. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
[TBL] [Abstract][Full Text] [Related]
5. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
Acc Chem Res; 2005 Dec; 38(12):911-21. PubMed ID: 16359163
[TBL] [Abstract][Full Text] [Related]
6. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
[TBL] [Abstract][Full Text] [Related]
7. Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins.
Schneider F; Hammarström P; Kelly JW
Protein Sci; 2001 Aug; 10(8):1606-13. PubMed ID: 11468357
[TBL] [Abstract][Full Text] [Related]
8. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
[TBL] [Abstract][Full Text] [Related]
10. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
11. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
[TBL] [Abstract][Full Text] [Related]
12. Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.
Robinson LZ; Reixach N
Biochemistry; 2014 Oct; 53(41):6496-510. PubMed ID: 25245430
[TBL] [Abstract][Full Text] [Related]
13. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Green NS; Foss TR; Kelly JW
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
[TBL] [Abstract][Full Text] [Related]
14. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
Sekijima Y; Dendle MA; Kelly JW
Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis for transthyretin amyloidosis.
de Lartigue J
Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
[TBL] [Abstract][Full Text] [Related]
16. Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response.
Monteiro C; Mesgarzadeh JS; Anselmo J; Fernandes J; Novais M; Rodrigues C; Powers DL; Powers ET; Coelho T; Kelly JW
Amyloid; 2023 Mar; 30(1):81-95. PubMed ID: 36178172
[TBL] [Abstract][Full Text] [Related]
17. Tafamidis (Vyndaqel): a light for FAP patients.
Nencetti S; Rossello A; Orlandini E
ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.
Connelly S; Choi S; Johnson SM; Kelly JW; Wilson IA
Curr Opin Struct Biol; 2010 Feb; 20(1):54-62. PubMed ID: 20133122
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
Sekijima Y; Kelly JW; Ikeda S
Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]